After last year’s high viral season with RSV, COVID-19 and flu straining hospital capacity, the FDA has approved four RSV vaccines — two for adults 60 and older, one for toddlers and another for pregnant people to protect newborns.
Every year, between 6,100 and 10,300 people die after contracting RSV, according to the CDC. The new approvals offered a hope of lessening the burden, but insurance companies might be getting in the way.
Medicare Part D covers the vaccine, but Medicare Part B doesn’t, according to the Times. Some private payers aren’t covering the shot, including Anthem Blue Cross Blue Shield, and older adults told the Times they left their pharmacy appointments without the vaccine because of the cost.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.